New York, December 13, 2004 – Pfizer Inc today announced results of a comprehensive six-year review of efficacy and safety data for DETROL® LA (tolterodine tartrate extended release capsules) ...

NEW YORK, August 20 - Women with mixed incontinence, a combination of overactive bladder and stress incontinence, reported a greater treatment benefit for overactive bladder symptoms from DETROL® LA ...

Pfizer and Impax Laboratories have reached an undisclosed accommodation on if and when Impax will be able to launch a generic of Pfizer's bladder-control drug Detrol LA. Detrol and the ...

Global pharmaceutical company Pfizer has announced that it has settled its litigation against Mylan Pharmaceuticals relating to Pfizer’s patents covering Detrol LA (tolterodine tartrate) ...

WALTHAM, Mass., April 3, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on ...

LOS ANGELES (Reuters) - Pfizer Inc_ is suing Impax Laboratories for infringing the world's largest drugmaker's patent on overactive bladder drug Detrol LA. In a lawsuit filed on Tuesday, Pfizer said ...

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of the Authorized Generic of Detrol®* LA (tolterodine tartrate extended-release capsules) 2 mg ...

PITTSBURGH — Mylan has launched a generic version of a drug made by Pfizer for treating bladder problems, the company said Tuesday. Mylan announced the launch of tolterodine tartrate extended-release ...

PITTSBURGH (AP) — Mylan Inc. said Thursday that it is now selling a generic version of Pfizer Inc.’s overactive bladder drug Detrol. The company said it started shipping its generic after receiving ...

NEW YORK (AP) -- Mylan Inc. plans to start selling a generic version of Pfizer Inc.'s overactive bladder drug Detrol LA in early 2014, as the two drugmakers said Friday they have resolved lawsuits ...